Introduction to the effects and efficacy of talazoparib

Talazoparib (Talzenna) is an FDA (U.S. Food and Drug Administration)-approved drug produced by Pfizer. As a poly(ADP-ribose) polymerase (PARP) enzyme inhibitor, the drug mainly acts on PARP1 and PARP2, two enzymes that play key roles in DNA repair. Preclinical studies have shown that talazoparib can accurately block the activity of PARP enzyme, thereby capturing PARP at the site of DNA damage, thereby interfering with the DNA repair mechanism of cancer cells. This mechanism of action prevents cancer cells from effectively repairing DNA damage, ultimately leading to slowed growth of cancer cells and death of cancer cells. Clinical trials have shown that the drug has excellent therapeutic effects and safety, bringing new treatment options to breast and prostate cancer patients around the world.

In the treatment of breast cancer, talazoparib (Talzenna) is approved by the FDA as a single agent for the treatment of adult patients with deleterious or suspected deleterious germline BRCA mutation (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. This specific genetic mutation makes cancer cells defective in DNA repair, and talazoparib targets this defect. By blocking the activity of PARP enzyme, talazoparib can accelerate the death of cancer cells, thereby significantly extending the progression-free survival of patients.

In the treatment of prostate cancer, talazoparib (Talzenna) is used in combination with enzalutamide to treat adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC). This combined treatment plan can further improve the treatment effect and bring better quality of life to patients.

In short, talazoparib (Talzenna) has shown great potential in the field of cancer treatment with its significant clinical effects. Whether used as a single agent or in combination, the drug can bring new treatment options and hope to patients. Currently, talazoparib is only sold overseas. Pfizer's original drug is slightly more expensive, but there are affordable generic drug options in Laos. Patients should choose according to their needs.